AI-enhanced breast MRI with a 75% reduced gadolinium dose maintained diagnostic sensitivity comparable to full-dose protocols.
Key Details
- 1Single-center study with 20 female participants having biopsy-proven malignancies or high-risk indications.
- 2Low-dose (0.025 mmol/kg) MRI scans with AI were compared to standard-dose (0.1 mmol/kg) with/without AI.
- 3Diagnostic sensitivity with low-dose + AI was 83.3% (p=1 vs. standard), accuracy was 74.5% vs. 69.5% (standard) and 65.5% (standard+AI).
- 498 lesions detected; 12 were biopsy-proven malignancies; high NPVs (93-94%) across all protocols.
- 5AI-assisted low-dose MRI had the highest PPV (50%) and substantial interreader agreement (kappa 0.65-0.74).
- 6Study was small and lacked long-term outcome data; funded by Bracco.
Why It Matters
Gadolinium retention and cost are growing concerns in breast imaging. This study shows that AI-powered image enhancement could allow safer, lower-dose protocols without compromising cancer detection, marking a significant step for both patient safety and clinical feasibility.
Source
AuntMinnie
Related News
•Radiology Business
Study Highlights Limitations of AI in Prostate MRI Screening
New research points to several shortcomings in implementing AI for MRI-based prostate cancer screening.
•AuntMinnie
Deep Learning Model Predicts Brain Tumor MRI Enhancement Without Gadolinium
German researchers developed a deep learning approach to predict MRI contrast enhancement in brain tumors without the need for gadolinium-based agents.
•Radiology Business
SimonMed Imaging Introduces Paid AI Add-Ons for Routine Exams
SimonMed Imaging is launching new AI-powered elective services for routine imaging exams with additional out-of-pocket costs for patients.